URGN
UroGen Pharma Ltd.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Buy
+31/100
Last price
41.60
▼ 1.18 (2.76%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
41.60
Prev close
42.78
Day high
43.54
Day low
41.11
Volume
764.43K
Market cap
$2.03B
P/E (TTM)
—
52W range
15.86 – 50.81
Day trading desk
Gap from prior close
-2.76%
Prior close 42.78
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
41.60 – 41.60
Position in range
—
—
ATR (14D)
1.71
4.10% of price
Prior day high
42.90
PDH
Prior day low
40.50
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 830.75K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+2.42%
+0.5%
1M
-6.03%
-7.2%
3M
+8.94%
+4.4%
6M
+129.78%
+111.6%
YTD
+76.90%
+62.7%
1Y
+138.10%
+121.7%
3Y
+195.72%
+113.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on URGN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-79.29K
Net selling
Buy transactions
5
19.00K shares
Sell transactions
7
98.29K shares
Net transactions
+12
Buys less sells
Sell : buy shares
5.2 : 1
Heavily one-sided
Insider-held shares
1.71M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 8, 26 | SCHOENBERG MARK Officer |
SELL | 871 | $37.38K | Direct |
| Sep 8, 26 | SMITH JASON DREW General Counsel |
SELL | 1.52K | $64.62K | Direct |
| Sep 4, 26 | SCHOENBERG MARK Officer |
— | 1.67K | — | Direct |
| Sep 4, 26 | SMITH JASON DREW General Counsel |
— | 3.33K | — | Direct |
| Aug 26, 26 | ROBINSON JAMES A JR. Director |
— | 2.00K | — | Direct |
| Aug 20, 26 | SCHOENBERG MARK Officer |
SELL | 60.68K | $2.85M | Direct |
| Jul 9, 26 | SCHOENBERG MARK Officer |
SELL | 10.00K | $400.00K | Direct |
| Jun 22, 26 | SCHOENBERG MARK Officer |
SELL | 10.00K | $350.10K | Direct |
| Jun 8, 26 | SCHOENBERG MARK Officer |
— | 10.00K | — | Direct |
| Jun 8, 26 | SCHOENBERG MARK Officer |
SELL | 5.22K | $142.56K | Direct |
| May 26, 26 | ROBINSON JAMES A JR. Director |
— | 2.00K | — | Direct |
| May 8, 26 | SCHOENBERG MARK Officer |
SELL | 10.00K | $300.00K | Direct |
| Feb 3, 26 | SCHOENBERG MARK Officer |
SELL | 7.37K | $145.17K | Direct |
| Feb 3, 26 | SMITH JASON DREW General Counsel |
SELL | 7.48K | $147.26K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BUTITTA CYNTHIA M |
Director | 2.00K | Conversion of Exercise of derivative security |
DEGNAN CHRISTOPHER |
Chief Financial Officer | 2.28K | Conversion of Exercise of derivative security |
HOLDEN STUART M.D. |
Director | 2.00K | Conversion of Exercise of derivative security |
ROBINSON JAMES A JR. |
Director | 8.00K | Conversion of Exercise of derivative security |
SCHOENBERG MARK |
Officer | 59.88K | Sale |
SMITH JASON DREW |
General Counsel | 53.14K | Sale |
WEN LEANA |
Director | 2.00K | Conversion of Exercise of derivative security |
WILDMAN DANIEL GEORGE |
Director | 2.00K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$2.03B
Enterprise value$2.11B
Revenue (TTM)$188.73M
Gross profit$171.46M
EBITDA$-66.34M
Net income$-97.64M
EPS (TTM)$-1.97
Free cash flow$-106.98M
Total cash$107.97M
Total debt$196.13M
Book value / share$-2.71
Shares outstanding48.88M
Float43.41M
Short % of float13.04%
Dividend yield0.00%
Beta (5Y)1.58
Valuation & profitability ratios
Trailing P/E—
Forward P/E14.83
PEG ratio—
Price / sales—
Price / book—
EV / revenue11.20
EV / EBITDA-31.85
Gross margin90.84%
Operating margin0.15%
Profit margin-51.73%
Return on equity—
Return on assets-18.06%
Debt / equity—
Current ratio3.80
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $109.79M | $90.40M | $82.71M | $64.36M | +21.4% |
| Operating revenue | $109.79M | $90.40M | $82.71M | $64.36M | +21.4% |
| Cost of revenue | $12.45M | $8.88M | $9.36M | $7.65M | +40.2% |
| Gross profit | $97.34M | $81.52M | $73.35M | $56.70M | +19.4% |
| Research & development | $67.11M | $57.15M | $45.61M | $52.91M | +17.4% |
| Selling, general & admin | $155.10M | $121.15M | $93.27M | $82.84M | +28.0% |
| Total operating expense | $222.20M | $178.30M | $138.89M | $135.74M | +24.6% |
| Operating income | -$124.86M | -$96.78M | -$65.54M | -$79.04M | -29.0% |
| Net interest income | -$27.88M | -$27.03M | -$33.63M | -$29.06M | -3.2% |
| Pre-tax income | -$153.42M | -$124.04M | -$98.32M | -$108.03M | -23.7% |
| Tax provision | $78.00K | $2.83M | $3.92M | $1.75M | -97.2% |
| Net income | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -21.0% |
| Net income to common | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -21.0% |
| Basic EPS | -3.19 | -2.96 | -3.55 | -4.79 | -7.8% |
| Diluted EPS | -3.19 | -2.96 | -3.55 | -4.79 | -7.8% |
| EBIT | -$138.07M | -$111.52M | -$83.61M | -$99.59M | -23.8% |
| EBITDA | -$135.66M | -$110.33M | -$81.90M | -$97.77M | -23.0% |
| Basic shares | 48.12M | 42.88M | 28.83M | 22.81M | +12.2% |
| Diluted shares | 48.12M | 42.88M | 28.83M | 22.81M | +12.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $110.75M | $171.99M | $95.00M | $55.41M | -35.6% |
| Cash & short-term investments | $120.46M | $236.69M | $136.97M | $99.96M | -49.1% |
| Accounts receivable | $33.08M | $20.30M | $15.44M | $12.70M | +62.9% |
| Inventory | $16.46M | $9.23M | $5.67M | $4.33M | +78.4% |
| Total current assets | $186.02M | $276.13M | $169.19M | $128.91M | -32.6% |
| Property, plant & equipment | $9.09M | $3.79M | $2.36M | $3.75M | +140.0% |
| Total assets | $200.46M | $285.71M | $178.31M | $135.62M | -29.8% |
| Total current liabilities | $46.42M | $45.95M | $31.21M | $23.92M | +1.0% |
| Long-term debt | $122.21M | $121.73M | $98.55M | $97.54M | +0.4% |
| Total debt | $128.33M | $123.39M | $99.39M | $99.12M | +4.0% |
| Total liabilities | $305.93M | $294.51M | $243.52M | $224.98M | +3.9% |
| Retained earnings | -$959.72M | -$806.22M | -$679.35M | -$577.10M | -19.0% |
| Shareholder equity | -$105.47M | -$8.80M | -$65.21M | -$89.36M | -1,098.2% |
| Working capital | $139.61M | $230.19M | $137.97M | $104.99M | -39.4% |
| Net tangible assets | -$105.47M | -$8.80M | -$65.21M | -$89.36M | -1,098.2% |
| Shares issued | 48.35M | 42.23M | 32.49M | 23.13M | +14.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$153.49M | -$126.87M | -$102.24M | -$109.78M | -21.0% |
| Depreciation & amortisation | $2.41M | $1.19M | $1.71M | $1.82M | +103.3% |
| Stock-based compensation | $11.96M | $13.11M | $9.34M | $10.58M | -8.8% |
| Change in working capital | -$27.91M | $4.93M | $3.34M | -$6.31M | -665.9% |
| Operating cash flow | -$162.44M | -$96.77M | -$76.38M | -$87.56M | -67.9% |
| Capital expenditure | -$289.00K | -$295.00K | -$194.00K | -$254.00K | +2.0% |
| Investing cash flow | $61.56M | -$20.61M | -$953.00K | $1.06M | +398.6% |
| Financing cash flow | $39.92M | $194.62M | $116.93M | $97.13M | -79.5% |
| Free cash flow | -$162.73M | -$97.06M | -$76.57M | -$87.81M | -67.7% |
| End cash position | $112.09M | $173.06M | $95.82M | $56.22M | -35.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $72.46M | $50.96M | $37.84M | $27.48M | $24.21M | +42.2% |
| Operating revenue | $72.46M | $50.96M | $37.84M | $27.48M | $24.21M | +42.2% |
| Cost of revenue | $6.57M | $4.14M | $3.29M | $3.28M | $3.55M | +58.8% |
| Gross profit | $65.88M | $46.82M | $34.55M | $24.20M | $20.66M | +40.7% |
| Research & development | $17.34M | $15.60M | $14.31M | $14.01M | $18.91M | +11.1% |
| Selling, general & admin | $48.44M | $51.49M | $39.35M | $37.58M | $43.20M | -5.9% |
| Total operating expense | $65.77M | $67.08M | $53.66M | $51.59M | $62.11M | -2.0% |
| Operating income | $111.00K | -$20.26M | -$19.11M | -$27.39M | -$41.45M | +100.5% |
| Net interest income | -$8.49M | -$7.76M | -$7.52M | -$6.82M | -$7.10M | -9.4% |
| Pre-tax income | -$8.72M | -$28.35M | -$26.64M | -$34.40M | -$48.92M | +69.2% |
| Tax provision | $5.63M | -$4.77M | -$275.00K | -$1.05M | $1.01M | +218.0% |
| Net income | -$14.35M | -$23.57M | -$26.36M | -$33.35M | -$49.94M | +39.1% |
| Net income to common | -$14.35M | -$23.57M | -$26.36M | -$33.35M | -$49.94M | +39.1% |
| Basic EPS | -0.28 | -0.47 | -0.54 | -0.69 | -1.05 | +40.4% |
| Diluted EPS | -0.28 | -0.47 | -0.54 | -0.69 | -1.05 | +40.4% |
| EBIT | -$3.83M | -$24.16M | -$22.87M | -$31.03M | -$44.79M | +84.1% |
| EBITDA | -$3.17M | -$23.51M | -$22.19M | -$30.39M | -$44.20M | +86.5% |
| Basic shares | 50.38M | 50.18M | 49.23M | 48.06M | 47.74M | +0.4% |
| Diluted shares | 50.38M | 50.18M | 49.23M | 48.06M | 47.74M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.13M | $109.97M | $110.75M | $90.04M | $92.90M | -28.0% |
| Cash & short-term investments | $107.97M | $140.27M | $120.46M | $127.03M | $156.95M | -23.0% |
| Accounts receivable | $88.76M | $55.41M | $33.08M | $19.70M | $19.65M | +60.2% |
| Inventory | $24.59M | $20.92M | $16.46M | $8.34M | $7.13M | +17.5% |
| Total current assets | $235.43M | $237.46M | $186.02M | $168.55M | $196.87M | -0.9% |
| Property, plant & equipment | $8.22M | $8.56M | $9.09M | $9.18M | $6.24M | -3.9% |
| Total assets | $252.59M | $253.69M | $200.46M | $185.05M | $208.72M | -0.4% |
| Total current liabilities | $61.91M | $50.63M | $46.42M | $42.24M | $47.55M | +22.3% |
| Long-term debt | $188.73M | $189.53M | $122.21M | $122.11M | $122.51M | -0.4% |
| Total debt | $196.13M | $195.18M | $128.33M | $128.35M | $125.92M | +0.5% |
| Total liabilities | $384.99M | $377.94M | $305.93M | $300.45M | $302.09M | +1.9% |
| Retained earnings | -$997.64M | -$983.29M | -$959.72M | -$933.35M | -$900.00M | -1.5% |
| Shareholder equity | -$132.40M | -$124.25M | -$105.47M | -$115.41M | -$93.38M | -6.6% |
| Working capital | $173.51M | $186.83M | $139.61M | $126.30M | $149.32M | -7.1% |
| Net tangible assets | -$132.40M | -$124.25M | -$105.47M | -$115.41M | -$93.38M | -6.6% |
| Shares issued | 48.87M | 48.71M | 48.35M | 46.78M | 46.20M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$14.35M | -$23.57M | -$26.36M | -$33.35M | -$49.94M | +39.1% |
| Depreciation & amortisation | $668.00K | $652.00K | $679.00K | $639.00K | $596.00K | +2.5% |
| Stock-based compensation | $5.33M | $4.63M | $3.13M | $3.03M | $2.73M | +15.2% |
| Change in working capital | -$24.57M | -$30.08M | -$17.06M | -$13.50M | $5.24M | +18.3% |
| Operating cash flow | -$33.01M | -$45.32M | -$38.33M | -$42.27M | -$39.83M | +27.2% |
| Capital expenditure | -$60.00K | -$54.00K | -$17.00K | -$87.00K | -$141.00K | -11.1% |
| Investing cash flow | $1.67M | -$20.69M | $27.72M | $31.40M | $28.41M | +108.1% |
| Financing cash flow | $500.00K | $65.20M | $31.32M | $8.27M | $296.00K | -99.2% |
| Free cash flow | -$33.07M | -$45.37M | -$38.34M | -$42.36M | -$39.97M | +27.1% |
| End cash position | $80.46M | $111.30M | $112.09M | $91.39M | $93.99M | -27.7% |
Options analytics
Put / call volume
3.93
Put-heavy session
Put / call open interest
0.41
Positioning, not flow
Max pain
45.00
+8.6% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
43
Contracts, this expiry
Put volume
169
Contracts, this expiry
Heaviest call OI
45.00
140 contracts
Heaviest put OI
47.00
31 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.27 | -0.28 | -5.7% |
| Mar 2026 | -0.48 | -0.47 | +2.6% |
| Dec 2025 | -0.51 | -0.53 | -3.6% |
| Sep 2025 | -0.68 | -0.69 | -1.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.09 | 7 | $90.58M | +229.6% |
| Next quarter | 0.39 | 7 | $108.23M | +186.0% |
| Current year | -0.24 | 7 | $322.20M | +193.5% |
| Next year | 2.79 | 7 | $541.49M | +68.1% |
Analyst targets & ownership
Mean target$60.00
High target$75.00
Low target$48.00
Implied upside44.23%
Analyst count8
ConsensusSTRONG BUY
Strong buy / Buy1 / 6
Hold1
Sell / Strong sell0 / 0
Held by insiders3.49%
Held by institutions97.71%
Institutions holding260
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
41.24
+0.89% from price
SMA 20
42.15
-1.70% from price
SMA 50
43.86
-5.55% from price
SMA 100
38.85
+7.07% from price
SMA 200
30.12
+37.57% from price
EMA 12
41.72
-0.30% from price
EMA 26
42.41
-1.91% from price
EMA 50
42.02
-1.00% from price
RSI (14)
44.9
Neutral
MACD (12,26,9)
-0.69
Hist 0.01
ATR (14)
1.71
4.12% of price
Realised vol 30D
34.1%
Annualised
Bollinger upper
44.55
20, 2σ
Bollinger lower
39.74
20, 2σ
50 / 200 cross
Golden
43.86 vs 30.12
Trend bias
Above 200
+37.57%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.20
More volatile than market
Correlation to SPY
0.25
Largely independent
Realised vol 30D
34.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-42.2%
Peak to trough
Max drawdown 5Y
-82.6%
Peak to trough
ATR 14
1.71
4.12% of price
Beta (reported)
1.58
5Y monthly, from filing
Short interest
Shares short
6.25M
Prior 5.12M
Change vs prior
+22.0%
Shorts adding
% of float
13.04%
Elevated
% of shares out
12.78%
Against total outstanding
Days to cover
7.6
Crowded exit
Float
43.41M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 6, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 5, 26 | TD Cowen | MAINTAINED | Buy | Buy |
| Jul 21, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jul 16, 26 | Oppenheimer | MAINTAINED | Outperform | Outperformer |
| Jun 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 18, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 7, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Mar 31, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Mar 2, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
| Jan 23, 26 | D. Boral Capital | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-20
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-23
Corporate Changes & Voting Matters
8-K · 2026-06-02
Annual Report to Shareholders
ARS · 2026-05-27
Corporate Changes & Voting Matters
8-K · 2026-05-06
Proxy Statements
DEF 14A · 2026-04-30
Proxy Statements
PRE 14A · 2026-04-17
Headlines
Here's Why You Should Add URGN Stock to Your Portfolio Now
Zacks · 7d ago
UroGen Pharma (URGN) Stock Looks Fairly Valued On Its Sales Base
Simply Wall St. · 12d ago
Is Establishment Labs’ (ESTA) Profitability Inflection the Ultimate Buying Opportunity?
Insider Monkey · 14d ago
Is UroGen’s (URGN) Commercial Engine Strong Enough To Fund Its Pipeline Ambitions?
Insider Monkey · 14d ago
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
Barrons.com · 28d ago
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 33d ago
UroGen Pharma to Present at Upcoming Investor Conferences
GlobeNewswire · 35d ago
Urogen Pharma Insider Sold Shares Worth $2,854,853, According to a Recent SEC Filing
MT Newswires · 44d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.